ENHO, recognized by its official name as "energy homeostasis associated", is a molecule intricately associated with enabling hormone activity, especially within the realm of cellular signaling. Functioning as a linchpin in the Notch signaling pathway, ENHO plays a pivotal role in its positive regulation. Found predominantly within the extracellular region and demonstrating pronounced activity in the plasma membrane, ENHO is believed to be instrumental in orchestrating myriad biological processes and coordinating cellular events through its involvement in Notch signaling. The precise locale of ENHO and its interaction with the intricate Notch signaling pathway places it at a crossroads of cellular communication, where its regulatory role can influence various cellular decisions.
ENHO inhibitors is a class of chemicals designed to modulate the activity of ENHO, often by attenuating or intercepting its role in the Notch signaling pathway. Typically, these inhibitors exert their influence by hindering specific stages of the Notch signaling cascade. For instance, some ENHO inhibitors might target the pivotal enzymes involved in the release of essential signaling components, which disrupts the chain of events that lead to downstream signaling. Others could block the interactions between ENHO and its partner molecules, ensuring the signaling remains in a dormant state. Certain members of this class could alter the stability or integrity of ENHO, ensuring it remains inactive or is degraded before it can initiate signaling. These diverse modes of action collectively serve to regulate the activity of ENHO, ensuring the fine-tuned control of the Notch signaling pathway and its consequent cellular effects.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
DAPT | 208255-80-5 | sc-201315 sc-201315A sc-201315B sc-201315C | 5 mg 25 mg 100 mg 1 g | $40.00 $120.00 $480.00 $2141.00 | 47 | |
DAPT is a gamma-secretase inhibitor that prevents Notch intracellular domain (NICD) release, thus disrupting Notch signaling. | ||||||
RO-4929097 | 847925-91-1 | sc-364602 sc-364602A | 10 mg 50 mg | $439.00 $1417.00 | 1 | |
RO4929097 is another gamma-secretase inhibitor, preventing the activation of Notch target genes. | ||||||
Dibenzazepine (Deshydroxy LY 411575) | 209984-56-5 | sc-207554 sc-207554A | 2 mg 5 mg | $235.00 $260.00 | 4 | |
DBZ selectively inhibits gamma-secretase, leading to a reduction in Notch signaling. | ||||||
LY411575 | 209984-57-6 | sc-364529 sc-364529A | 10 mg 50 mg | $198.00 $473.00 | 6 | |
This is a potent gamma-secretase inhibitor, targeting multiple Notch receptors and reducing their signaling. | ||||||
FLI-06 | 313967-18-9 | sc-497529 | 5 mg | $82.00 | ||
A novel compound that disrupts Notch trafficking and processing before gamma-secretase cleavage. | ||||||
BMS-906024 | 1401066-79-2 | sc-507372 | 10 mg | $3600.00 | ||
It is a gamma-secretase inhibitor that reduces NICD production, inhibiting Notch signaling. | ||||||
L-685,458 | 292632-98-5 | sc-204042 sc-204042A | 1 mg 5 mg | $337.00 $1000.00 | 4 | |
This inhibitor targets gamma-secretase, thereby reducing cleavage of the Notch receptor and its subsequent signaling. | ||||||
MK-0752 | 471905-41-6 | sc-364534 sc-364534A | 10 mg 50 mg | $592.00 $1550.00 | ||
MK-0752 is a gamma-secretase inhibitor that reduces the activation of Notch-dependent genes. | ||||||
PF-3084014 | 1290543-63-3 | sc-507501 | 5 mg | $130.00 | ||
Another gamma-secretase inhibitor, it disrupts Notch receptor cleavage and downstream signaling. | ||||||
SAHM1 | 2050906-89-1 | sc-507534 | 5 mg | $1435.00 | ||
A direct inhibitor of Notch transcription complex, SAHM1 prevents the transcription of Notch target genes. | ||||||